Candel Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
CADL$9.49+8.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| YEAR ENDED DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $30,496 | $19,314 |
| General and administrative | 17,770 | 14,057 |
| Total operating expenses | 48,266 | 33,371 |
| Loss from operations | (48,266) | (33,371) |
| Other income (expense): | ||
| Grant income | 89 | — |
| Interest income | 3,915 | 1,086 |
| Interest expense | (2,119) | (2,090) |
| Change in fair value of warrant liabilities | 8,199 | (20,802) |
| Total other income (expense), net | 10,084 | (21,806) |
| Net loss and comprehensive loss | $(38,182) | $(55,177) |
| Net loss per share, basic and diluted | $(0.72) | $(1.74) |
| Weighted-average common shares outstanding, basic and diluted | 52,958,644 | 31,675,076 |
Candel ThErapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.